Loading...
•
Sep 30, 2024
scPharmaceuticals Q3 2024 Earnings Report
scPharmaceuticals reported Q3 2024 results, with FUROSCIX revenue increasing and progress made on label expansion and autoinjector program.
Key Takeaways
scPharmaceuticals reported a net FUROSCIX revenue of $10.0 million for Q3 2024, a 164% increase compared to Q3 2023. The company also received approval for label expansion to include NYHA Class IV patients and announced positive data on its Autoinjector program. A transformative financing of $125 million is expected to fund operations through expected profitability. The company reported a net loss of $35.1 million, or $0.75 per share, which included one-time charges of $0.47 per share.
Net FUROSCIX revenue reached $10.0 million, up 164% from Q3 2023.
Label expansion approved to include New York Heart Association (NYHA) Class IV Patients.
Positive pharmacokinetic/pharmacodynamic (PK/PD) data reported for Autoinjector program.
Completed $125 million financing anticipated to fund the Company through expected profitability.
Revenue by Segment
Forward Guidance
scPharmaceuticals is focused on expanding the FUROSCIX indication, developing the Autoinjector, and advancing pre-launch activities for patients with fluid overload due to CKD.
Positive Outlook
- Continued growth of FUROSCIX net revenue.
- Increased penetration into the Class IV chronic heart failure patient population.
- Expansion of the sales force completed in late September.
- Significant increase in the FUROSCIX purchase flow from IDNs and hospital systems.
- Advancing pre-launch activities in anticipation of PDUFA target action date on March 6, 2025, in patients with fluid overload due to CKD.
Challenges Ahead
- Dependence on the commercial success of FUROSCIX.
- Risks related to the receipt of regulatory approval for product candidates.
- Risks related to the ability to manufacture sufficient product for commercialization.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...